Does withdrawal of ACEi/ARB increase postdischarge mortality and readmission in hospitalized patients with heart failure with reduced ejection fraction compared to continuation?
Withdrawal of ACEi/ARB during hospitalization for HFrEF is associated with worse postdischarge outcomes compared to continuation, supporting guideline recommendations to continue therapy.
BACKGROUND: Guidelines recommend continuation or initiation of guideline-directed medical therapy, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB), in hospitalized patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: <0.001) for patients not started on therapy. CONCLUSIONS: Compared with continuation, withdrawal of ACEi/ARB during heart failure hospitalization is associated with higher rates of postdischarge mortality and readmission, even after adjustment for severity of illness.
Gilstrap et al. (Thu,) studied this question.